S. Pol

All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study

Michael Manns, S. Pol, Ira M. Jacobson et al. · The Lancet · 2014 · 343 citations

Pharmacy, Infectious Diseases, Hepatitis Pharmacotherapy +13

TNF alpha antagonist therapy and safety monitoring

Thao Pham, H. Bachelez, Jean‐Marie Berthelot et al. · Joint Bone Spine · 2011 · 69 citations

Pharmacy, Pharmacology, Pharmacotherapy +14

Tocilizumab: Therapy and safety management

Thao Pham, P Claudepierre, Arnaud Constantin et al. · Joint Bone Spine · 2010 · 60 citations

Pharmacy, Pharmacology, Pharmacotherapy +8

1373 FIRST REPORT OF SVR12 FOR A NS5A REPLICATION COMPLEX INHIBITOR BMS-790052 IN COMBINATION WITH PEG-IFNa-2A AND RBV: PHASE 2A TRIAL IN TREATMENT-NAIVE HCV-GENOTYPE-1 SUBJECTS

S. Pol, Reem Ghalib, Vinod K. Rustgi et al. · Journal of Hepatology · 2011 · 26 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +14

O166 ALL-ORAL DUAL THERAPY WITH DACLATASVIR AND ASUNAPREVIR IN PATIENTS WITH HCV GENOTYPE 1B INFECTION: PHASE 3 STUDY RESULTS

M.P. Manns, S. Pol, Ira M. Jacobson et al. · Journal of Hepatology · 2014 · 20 citations

Pharmacy, Infectious Diseases, Microbiology +11